Tisotumab vedotin (TV), the first ADC approved for the treatment of cervical cancer, consists of a human TF-specific mAb, a protease-cleavable linker, and the highly potent cytotoxic payload monomethyl auristatin E (MMAE)—a microtubule disrupting agent [60]. This evidence concerns the gene TF and cervical cancer.